5月20日，映恩生物-B盘中上涨5.66%，报227.4港元，成交额794.67万港元。消息面上，公司此前于5月12日向BioNTech发出书面通知行使DB-1311/BNT324美国市场独家成本及利润/亏损分担选择权，股价自公告后连续多日下挫，从约257港元跌至5月19日的210.4港元，累计跌幅超18%。今日盘中出现明显反弹，市场对短期超跌的修复需求释放。
DB-1311/BNT324为针对B7-H3靶点的新一代ADC候选药物，目前已在全球超600名患者中开展临床治疗，覆盖10余种适应症，全球III期临床试验正在推进中。行使选择权后公司需向BioNTech支付其分担的过往开发成本，市场此前对公司短期资金压力的担忧有所缓解。
（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.